Our delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific antibody* functions as a T-cell engager, acting as a bridge that selectively directs the activity of cytolytic T cells to DLL3-expressing tumor cells.1,2
Clinical trials (monotherapy): our DLL3/CD3 bispecific antibody is being investigated in patients with small cell lung cancer (SCLC) and other neuroendocrine tumors (NETs).3
DLL3 is an inhibitory Notch ligand that is expressed in tumors with a neuroendocrine origin, such as small-cell lung cancer (SCLC), glioblastoma multiforme, carcinoids and pediatric tumors – with no to minimal expression in normal tissue.4-6 Notch pathway signaling is involved in a variety of development processes, including the development of pulmonary neuroendocrine cells.5 DLL3 expression inhibits Notch signaling, which is downregulated during neuroendocrine tumor growth.5
Mechanism of action
Our DLL3/CD3 bispecific antibody acts as a T-cell engager with an extended half-life.1 The DLL3/CD3 bispecific antibody selectively directs the activity of cytolytic T cells to DLL3-expressing tumor cells.1,2
The pharmacological effect of the DLL3/CD3 bispecific antibody depends on its ability to bind simultaneously to CD3 on T cells and to DLL3 expressed on tumor cells, resulting in the formation of a cytolytic synapse.1,2
Preclinical studies have demonstrated the antitumor activity of the DLL3/CD3 bispecific antibody in a DLL3-positive tumor model of SCLC.2
The binding of the DLL3/CD3 bispecific antibody to CD3 may lead to programmed cell death protein 1 (PD-1) upregulation in activated T cells and programmed death-ligand 1 upregulation on malignant cells.2 Preclinical evidence supports the combination of the DLL3/CD3 bispecific antibody with PD-1 inhibitors (such as ezabenlimab) in order to revert this upregulation.1,2
Our DLL3/CD3 bispecific antibody is currently being investigated as a monotherapy in patients with SCLC and NETs in an ongoing Phase Ia study.3
|Trial number||Phase||Treatment||Patient population||Status|
DLL3/CD3 bispecific antibody
SCLC and other NETs
Boehringer Ingelheim. Data on file.
Hipp S, et al. Cancer Res 2019;79(13 Suppl.): Abstract 549.
ClinicalTrials.gov. NCT04429087. http://clinicaltrials.gov/ct2/show/NCT04429087 (Accessed: February 2021).
National Center for Biotechnology Information. DLL3 delta like canonical Notch ligand 3 [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/10683 (Accessed: February 2021).
Owen DH, et al. J Hematol Oncol 2019;12(1):61.
Saunders LR, et al. Sci Transl Med 2015;7(302):302ra136.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: March 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue